Resistance to the platinum-based chemotherapy drug, cisplatin, is significant setback in ovarian cancer. We engineered fatty acid-like Pt(IV) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry...

A spermine-conjugated lipophilic Pt(iv) prodrug is designed to induce mitochondrial damage and eliminate ovarian cancer stem cells.

This work demonstrates the development of “dual-action” organometallic polymeric nanoparticles (OPNPs) for treating drug-resistant ovarian cancer.